Direct chemosensitivity monitoring ex vivo on undissociated melanoma tumor tissue by impedance spectroscopy

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6408-6418

  Jahnke, Heinz Georg ^a   Poenick, Sarah ^a   Maschke, Jan ^b   Kendler, Michael ^b   Simon, Jan C ^b   Robitzki, Andrea A ^a  

^a Center for Biotechnology and Biomedicine   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TREOSULFAN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MELANOMA; METASTASIS; MONOLAYER CULTURE; PRIMARY TUMOR; TISSUE STRUCTURE; TUMOR BIOPSY; TUMOR CELL; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; PATHOLOGY; PROCEDURES;

DIELECTRIC SPECTROSCOPY; HUMANS; MELANOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84918590831     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0813     Document Type: Article

References (32)

1. Eggermont AM, Kirkwood JM Re-evaluating the role of dacarbazine in metastaticmelanoma: whathavewelearned in 30 years? Eur J Cancer. 2004; 40:1825-36.
2. Fruehauf JP. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002; 9:171-82.
3. Sharma S, Neale MH, DiNicolantonio F, Knight L.A., Whitehouse PA, Mercer SJ, et al. Outcomeof ATP-basedtumor chemosensitivityassay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC cancer 2003; 3:19.
4. Cree IA. Chemosensitivity and chemoresistance testing in ovarian cancer. Current Opin Obstet Gynecol 2009; 21:39-43.
5. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S Group TCAOCT. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007; 18:1093-101.
6. Singer CF, Klinglmuller F, Stratmann R., Staudigl C, Fink-Retter A, Gschwantler D, et al Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay. PloS ONE 2013; 8:e66573.
7. Ugurel S, Tilgen W, Reinhold U. Chemosensitivity testing in malignant melanoma. Recent Results Cancer Res 2003; 161:81-92.
8. Ugurel S, Schadendorf D, Pfohler C., Neuber K, Thoelke A, Ulrich J., et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clinical Cancer Res 2006; 12:5454-63.
9. Neubauer H, Stefanova M, Solomayer E., Meisner C, Zwirner M, Wallwiener D., et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 2008; 28:949-55.
10. Smalley KS, Haass NK, Brafford P.A., Lioni M., Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-44.
11. Loessner D, Stok KS, Lutolf M.P., Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010; 31:8494-506.
12. Kimlin LC, Casagrande G, Virador VM In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2013; 52:167-82.
13. Myungjin Lee J., Mhawech-Fauceglia P, Lee N., Cristina Parsanian L, Gail Lin Y, Andrew Gayther S, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 2013; 93:528-42.
14. Han A, Yang L, Frazier AB Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clinical Cancer Res 2007; 13:139-43.
15. Krinke D, Jahnke HG, Panke O, Robitzki AA A microelectrode-based sensor for label-free in vitro detection of ischemic effects on cardio-myocytes. Biosens Bioelectron 2009; 24:2798-803.
16. Xiao X, Guo M, Li Q., Cai Q, Yao S, Grimes CA In-situ monitoring of breast cancer cell (MCF-7) growth and quantification of the cytotoxicity of anticancer drugs fluorouracil and cisplatin. Biosens Bioelectron 2008; 24:247-52.
17. Thielecke H, Mack A, Robitzki A. A multicellular spheroid-based sensor for anti-cancer therapeutics. Biosens Bioelectron 2001; 16:261-9.
18. Kloss D, Fischer M, Rothermel A., Simon JC, Robitzki AA. Drug testing on 3D in vitro tissues trapped on a microcavity chip. Lab Chip 2008; 8:879-84.
19. Kloss D, Kurz R, Jahnke H.G., Fischer M., Rothermel A, Anderegg U, et al Microcavity array (MCA)-based biosensor chip for functional drug screening of 3D tissue models. Biosens Bioelectron 2008; 23: 1473-80.
20. Haas S, Jahnke HG, Glass M, Azendorf R., Schmidt S, Robitzki AA. Real-time monitoring of relaxation and contractility of smooth muscle cells on a novel biohybrid chip. Lab Chip 2010; 10:2965-71.
21. Krinke D, Jahnke HG, Mack T.G., Hirche A., Striggow F, Robitzki AA. A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring. Biosens Bioelectron 2010; 26:162-8.
22. Andreotti PE, Cree IA, Kurbacher C.M., Hartmann DM, Linder D, Harel G, et al Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995; 55:5276-82.
23. Alberts DS, Chen HS Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Prog Clin Biol Res. 1980; 48: 351-9.
24. Parker KA, Glaysher S, Polak M., Gabriel FG, Johnson P, Knight LA, et al The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 2010; 63: 1012-20.
25. Gaggioli C, Sahai E. Melanoma invasion - current knowledge and future directions. Pigment Cell Res 2007; 20:161-72.
26. Olbryt M. Role of tumor microenvironment in the formation and progression of skin melanoma. Postepy Hig Med Dosw 2013; 67: 413-32.
27. Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem 2007; 101:862-72.
28. Botti G, Cerrone M, Scognamiglio G., Anniciello A, Ascierto PA, Cantile M. Microenvironment and tumor progression of melanoma: new therapeutic prospectives. J Immunotoxicol 2013; 10:235-52.
29. Brown E, McKee T, diTomaso E., Pluen A, Seed B, Boucher Y., et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003; 9:796-800.
30. Jahnke HG, Rothermel A, Sternberger I., Mack TG, Kurz RG, Panke O, et al An impedimetric microelectrode-based array sensor for label-free detection of tau hyperphosphorylation in human cells. Lab Chip 2009; 9:1422-8.
31. Jahnke HG, Heimann A, Azendorf R., Mpoukouvalas K, Kempski O, Robitzki A.A., et al. Impedance spectroscopy-an outstanding method for label-free and real-time discrimination between brain and tumor tissue in vivo. Biosens Bioelectron 2013; 46:8-14.
32. Godugu C, Patel AR, Desai U, Andey T., Sams A, Singh M. AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PloS ONE 2013; 8:e53708.